Therapeutic challenges of giant invasive cystic macroprolactinoma
Giant cystic prolactinomas are extremely rare. Dopamine agonists remain the first-line therapy for both giant and cystic prolactinomas. Early surgical intervention is indicated for vision-threatening conditions or in cases of dopamine agonist resistance.
Authors
- I. Rojbi (ORCID: https://orcid.org/0000-0002-4500-9020)
- I. Ben Naçef (ORCID: https://orcid.org/0000-0003-1609-7022)
- Sabrine Mekni (ORCID: https://orcid.org/0009-0006-3251-6038)
- H. Khiari
- Sofiene Bouali (ORCID: https://orcid.org/0000-0001-7388-7376)
- Sawsen Essayeh (ORCID: https://orcid.org/0000-0001-6636-0728)
- R. Laamouri
Institutions
- Hôpital Charles-Nicolle (TN)
- National Institute of Neurology Mongi-Ben Hamida (TN)
Publication Details
- Journal
- Endocrinology Diabetes and Metabolism Case Reports
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1530/edm-25-0091
- Citations
- 1
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.29